The invention discloses the application of lipid-lowering drugs in the treatment of hyperhomocysteinemia. It was found that HHcy could significantly promote the expression of autophagy, plasma cytochemical related genes and proteins in B lymphocyte, while autophagy and plasma cytochemical inhibitors were down-regulated, suggesting that HHcy could stimulate B lymphocyte autophagy and plasma cytochemistry. Pretreatment of B lymphocytes with lipid-lowering drugs reversed HHcy-induced up-regulation of autophagy, plasma cytochemistry-related genes and proteins and down-regulation of related inhibitors. It was also found that HHcy could significantly promote the secretion of anti_beta 2 GPI by B lymphocytes. Pretreatment with lipid-lowering drugs could reverse the effect of HHcy on the secretion of anti_beta 2 GPI by B lymphocytes. Anti_beta 2 GPI, as an anti-phospholipid antibody, can lead to elevated levels of anti-phospholipid antibodies in the blood, which can induce the risk of anti-phospholipid syndrome. Intervention with lipid-lowering drugs can prevent this risk. Lipid-lowering drugs can also reduce the inflammatory activation of macrophages by inhibiting the secretion of anti\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
【技术实现步骤摘要】
降脂药在高同型半胱氨酸血症治疗方面的应用
本专利技术属于医药领域,涉及降脂药在高同型半胱氨酸血症治疗方面的应用。
技术介绍
同型半胱氨酸(homocysteine,Hcy)是体内蛋氨酸代谢的中间产物,是一个含有巯基的非必需氨基酸。蛋氨酸代谢发生异常,会导致血中Hcy这一中间代谢产物的积累。如果血中Hcy水平上升高于10μM时,即定义为高同型半胱氨酸血症(hyperhomocysteinemia,HHcy)。已有研究证明,HHcy与包括心血管疾病在内的多种疾病有关。
技术实现思路
本专利技术的目的在于提供降脂药在高同型半胱氨酸血症治疗方面的应用。本专利技术的上述目的是通过下面的技术方案得以实现的:降脂药在制备抑制高同型半胱氨酸血症致B淋巴细胞自噬的药物中的应用。体内外研究发现,HHcy会显著促进B淋巴细胞自噬相关基因和蛋白的表达水平,自噬抑制因子则显著被下调,这表明HHcy在体和离体会刺激促进B淋巴细胞发生自噬。降脂药非诺贝特预处理B淋巴细胞可以逆转HHcy引起的自噬相关基因和蛋白上调以及自噬抑制因子下调。降脂药在制备抑制高同型半胱氨酸血症致B淋巴细胞浆细胞化的药物中的应用。本领域技术人员知道,当B淋巴细胞激活后会经过免疫球蛋白类型转化重组,最终分化成浆细胞。BLIMP1和IRF4具有促浆细胞化的作用,抑制B淋巴细胞浆细胞的分子包括BCL6和PAX5等;通过测定B淋巴细胞中BLIMP1、IRF4、BCL6和PAX5的表达水平可以反映B淋巴细胞的浆细胞化程度。体内外研究发现,HHcy会显著促进B淋巴细胞浆细胞化相关基因和蛋白的表达水平,浆细胞化抑制因子则显著被下调 ...
【技术保护点】
1.降脂药在制备抑制高同型半胱氨酸血症致B淋巴细胞自噬的药物中的应用。
【技术特征摘要】
1.降脂药在制备抑制高同型半胱氨酸血症致B淋巴细胞自噬的药物中的应用。2.降脂药在制备抑制高同型半胱氨酸血症致B淋巴细胞浆细胞化的药物中的应用。3.降脂药在制备抑制高同型半胱氨酸血症致B淋巴细胞分泌anti-β2GPI的药物中的应用。4.降脂药在制备抑制高同型半胱氨酸...
【专利技术属性】
技术研发人员:王宪,冯娟,姜长涛,张岩,邵钫钰,
申请(专利权)人:北京大学,
类型:发明
国别省市:北京,11
还没有人留言评论。发表了对其他浏览者有用的留言会获得科技券。